Astragali Radix in Prevention and Treatment of Heart Failure from PANoptosis： A Review
10.13422/j.cnki.syfjx.20250808
- VernacularTitle:基于泛凋亡探讨黄芪防治心力衰竭的研究进展
- Author:
Songlin NI
1
;
Mengyue WANG
1
;
Mo SUN
1
;
Qian CHEN
1
Author Information
1. Shandong University of Traditional Chinese Medicine（TCM）， Jinan 250355， China
- Publication Type:Journal Article
- Keywords:
PANoptosis;
Astragali Radix;
active components;
heart failure;
mechanism
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(17):276-284
- CountryChina
- Language:Chinese
-
Abstract:
Heart failure （HF）， as the terminal stage of most cardiovascular diseases， manifests with primary symptoms including dyspnea， fatigue， edema， and palpitations. With recurrent episodes and a protracted clinical course， HF imposes a substantial global disease burden. PANoptosis represents a distinctive form of programmed cell death （PCD） that integrates features of pyroptosis， apoptosis， and necroptosis， yet cannot be fully attributed to any single pathway among these three PCD modalities. Recent studies demonstrate significant dysregulation of PANoptosis-related genes during HF progression， positioning PANoptosis as both an emerging mechanism mediating HF pathogenesis and a novel therapeutic target. In recent years， traditional Chinese medicine （TCM） has gained substantial recognition for its therapeutic potential in HF management， offering advantages such as flexible compatibility， multi-target effects， and minimal adverse reactions. Astragali Radix， a representative Qi-invigorating and blood-activating herbal medicine， has demonstrated remarkable clinical efficacy in the treatment for various HF subtypes. Research reveals that its major bioactive components—including astragaloside Ⅳ， polysaccharide， quercetin， and calycosin—exhibit significant associations with the regulation of apoptosis， pyroptosis， and necroptosis pathways. This review systematically explores the therapeutic feasibility of Astragali Radix in the prevention and treatment of HF through the lens of PANoptosis mechanisms. By synthesizing recent advances in the mechanisms of Astragali Radix-derived bioactive compounds and Astragali Radix-containing compound prescriptions in modulating PANoptosis， this paper aim to provide critical insights for advancing the diagnosis and therapeutic strategies of HF.
